/
Neurology
Frontotemporal Dementia
10
Pipeline Programs↗
9
Active Trials↗
11
Companies Involved↗
Frontotemporal Dementia is an early-stage landscape with 10 programs across 11 companies. The most active players are Eli Lilly, Denali Therapeutics Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 25
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
35
clinical trials
Completed16 · 46%
Terminated5 · 14%
Recruiting4 · 11%
Active, not recruiting3 · 9%
Not yet recruiting2 · 6%
Unknown status2 · 6%
Other3 · 9%
Clinical Trials
Trial Activity
35 trials
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
Not yet recruiting·—·Phase 2·NCT07154485·15 enrolled
Oxytocin and Social Cognition in Frontotemporal Dementia
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT01002300·24 enrolled
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
Completed·—·Phase 3·NCT00594737·17 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)